Trials / Terminated
TerminatedNCT02683395
A Study of PLX51107 in Advanced Malignancies
A Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Plexxikon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX51107 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-09-01
- Completion
- 2018-09-01
- First posted
- 2016-02-17
- Last updated
- 2018-12-24
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02683395. Inclusion in this directory is not an endorsement.